Home » Miguel Martín de Bustamante

Miguel Martín de Bustamante

Principal, Value, Access, and Pricing

Mr. Martín de Bustamante works across the firm’s practices, with a focus on Value, Access, and Pricing. He has developed expertise across many related areas, including innovative contracting and access models, strategic product / portfolio positioning, IRP and commercial opportunity based launch sequencing, as well as value positioning across various therapeutic areas. Throughout his tenure at CBPartners, he has led the development of innovative pricing and market access strategies on behalf of major multinational pharmaceutical and biopharmaceutical companies launching major specialty brands in both developed and developing markets.

Geographically, Mr. Martín de Bustamante specialises within Latin America, Asia-Pac, Central and Eastern Europe, and the Middle East / North Africa, as well as the broader European region. He presently serves on CBPartners’ expert panel for all emerging markets, including leadership of the firm’s Latin America Centre of Excellence.

Mr. Martín de Bustamante holds a BA degree in Political Economics & Spanish from the University of California, Berkeley, and speaks both Spanish and English at native level fluency.

Connect with Miguel Martín de Bustamante


+1 415 623 2035


Published Articles

ISPOR Asia-Pacific 2020: Comparison of Healthcare Systems and Opportunities for Innovative Drugs Across India, Vietnam, and Indonesia

A research poster that aims to understand how various healthcare system archetypes in APAC markets (e.g., India, Vietnam, and Indonesia) lead to access for high-cost innovative oncology treatments.

ISPOR Annual 2020: Collaborative Approaches to Attain Healthcare Sustainability in Latin America

This research poster aims to identify hurdles to achieving healthcare sustainability in LA, review approaches taken by policy makers to control healthcare budgets and propose actionable solutions to attain sustainability that mutually benefit healthcare systems and industry.

WHO Stands to Benefit the most from the Biosimilars Prequalification Programme?